Evidence map›Paper›PMID 40297216›Full record

ReviewClinical and translational radiation oncology2025

Stereotactic body radiotherapy for early glottic cancers: Is this "The Way"?

Jennifer Le Guévelou, Audrey Larnaudie, Pierre Blanchard, Yoann Pointreau, Joël Castelli

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jennifer Le GuévelouLaboratoire de traitement de l'image et du signal, University of Rennes, France.
Audrey LarnaudieDepartment of Radiotherapy, Centre François Baclesse, Caen, France.
Pierre BlanchardDepartment of Radiotherapy, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France.
Yoann PointreauDepartment of Radiotherapy, Institut inter-régional de Cancérologie (ILC) - Centre jean Bernard, Centre de cancérologie de la Sarthe (CCS) - Clinique Victor Hugo, Le Mans, France.
Joël CastelliLaboratoire de traitement de l'image et du signal, University of Rennes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the past decades, several options have been designed in order to preserve vocal function in patients with early glottic cancer, such as transoral laser microsurgery, new surgical strategies such as partial laryngectomy and radiation therapy (RT). With the development of new radiation techniques enabling a more accurate delivery of radiation dose, and the possibility to deliver high dose per fraction while sparing adjacent organs-at-risks (OARs), stereotactic body radiotherapy (SBRT) is being increasingly tested in this disease setting. We aimed to shed light on this appealing strategy, as well as to underline both optimal target population and specific technical considerations.

Indexed as

Early glottic cancerStereotactic body radiotherapyToxicity

Identifiers

PMID40297216
PMCPMC12036060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.